Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Biocon Staying Firm On Insulins Path, Including Glargine

Oct 26 2018

• By Anju Ghangurde

Traveller — BIOCON STAYS FIRM ON PLANS FOR INSULIN GLARGINE FOR NOW

Related Content

Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Aug 01 2017

Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars

Oct 08 2018

Merck Steps Out Of Insulin Glargine Market, But Says It Remains Committed To Biosimilars

Oct 11 2018

Biocon To Buttress India Market Glargine Supply From Malaysia Site

Jul 06 2018

Related Companies

Merck & Co., Inc.

Biocon, Ltd.

Samsung Bioepis Co., Ltd.

Sanofi

Viatris Inc.

Amgen, Inc.

Additional Topics

India Asia Pacific Biosimilars Sales & Earnings Strategy Commercial BioPharmaceutical

More from Biosimilars

More from Products

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window